These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33910624)

  • 21. Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013.
    Head MG; Fitchett JR; Nageshwaran V; Kumari N; Hayward A; Atun R
    EBioMedicine; 2016 Jan; 3():180-190. PubMed ID: 26870829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CardioScape mapping the cardiovascular funding landscape in Europe.
    Pries AR; Naoum A; Habazettl H; Dunkel M; Preissner R; Coats CJ; Tornada A; Orso F; Van de Werf F; Wood DA; ; Van de Werf F; Wood DA; O'Kelly S; Craven J; Coats A; Sipido K; De Backer D; Wallentin L; Hasenfuss G; Della Sala L; Leggeri I; ; Wood DA; Van de Werf F; Jaarsma T; Elliott P; Pries AR; Madonna R; Kjeldsen K; Maggioni AP; Franco OH; Hills S; Pugliese F; De Bacquer D
    Eur Heart J; 2018 Jul; 39(25):2423-2430. PubMed ID: 28449050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRANSVAC research infrastructure - Results and lessons learned from the European network of vaccine research and development.
    Geels MJ; Thøgersen RL; Guzman CA; Ho MM; Verreck F; Collin N; Robertson JS; McConkey SJ; Kaufmann SHE; Leroy O
    Vaccine; 2015 Oct; 33(41):5481-5487. PubMed ID: 25667962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global funding trends for malaria research in sub-Saharan Africa: a systematic analysis.
    Head MG; Goss S; Gelister Y; Alegana V; Brown RJ; Clarke SC; Fitchett JRA; Atun R; Scott JAG; Newell ML; Padmadas SS; Tatem AJ
    Lancet Glob Health; 2017 Aug; 5(8):e772-e781. PubMed ID: 28668230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.
    Liu H; Frijlink HW; Huckriede A; van Doorn E; Schmidt E; Leroy O; Rimmelzwaan G; McCullough K; Whelan M; Hak E
    Vaccine; 2016 Nov; 34(48):5845-5854. PubMed ID: 27793486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
    Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
    BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Funding allocation to surgery in low and middle-income countries: a retrospective analysis of contributions from the USA.
    Gutnik L; Dieleman J; Dare AJ; Ramos MS; Riviello R; Meara JG; Yamey G; Shrime MG
    BMJ Open; 2015 Nov; 5(11):e008780. PubMed ID: 26553831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.
    Giannuzzi V; Landi A; Bosone E; Giannuzzi F; Nicotri S; Torrent-Farnell J; Bonifazi F; Felisi M; Bonifazi D; Ceci A
    BMJ Open; 2017 Sep; 7(9):e017358. PubMed ID: 28893754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ebola research funding: a systematic analysis, 1997-2015.
    Fitchett JR; Lichtman A; Soyode DT; Low A; Villar de Onis J; Head MG; Atun R
    J Glob Health; 2016 Dec; 6(2):020703. PubMed ID: 27909582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of US National Institute of Health and European Union FP7 Projects on Active Ageing and Elderly Quality of Life-Author's reply.
    Carta MG; Atzeni M; Perra A; Mela Q; Piras M; Testa G; Orrù G; Kirilov I
    Clin Pract Epidemiol Ment Health; 2019; 15():10-14. PubMed ID: 30972137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development.
    Kaufmann SHE; Dockrell HM; Drager N; Ho MM; McShane H; Neyrolles O; Ottenhoff THM; Patel B; Roordink D; Spertini F; Stenger S; Thole J; Verreck FAW; Williams A;
    Front Immunol; 2017; 8():1203. PubMed ID: 29046674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited alignment of publicly competitive disease funding with disease burden in Japan.
    Nomura S; Yoneoka D; Tanaka S; Makuuchi R; Sakamoto H; Ishizuka A; Nakamura H; Kubota A; Shibuya K
    PLoS One; 2020; 15(2):e0228542. PubMed ID: 32040510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
    Fears R; Kaufmann S; Ter Meulen V; Zumla A;
    Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investing in acute health services: is it time to change the paradigm?
    Kerr R; Hendrie DV; Moorin R
    Aust Health Rev; 2014 Nov; 38(5):533-40. PubMed ID: 25164470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resource allocation to brain research in Europe (RABRE).
    Sobocki P; Lekander I; Berwick S; Olesen J; Jönsson B
    Eur J Neurosci; 2006 Nov; 24(10):2691-3. PubMed ID: 17156195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
    Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
    Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.